Peptide dosage charts
Dose range, how often, how long, and the units to draw. Every number says where it comes from: a drug label, a trial, or what people commonly report.
| Peptide | Typical dose | How often | Basis |
|---|---|---|---|
| 5-Amino-1MQfat mass and metabolic markers in obese mice, muscle cell work | 20 mg/kg subcutaneous / day | once or twice daily | animal study |
| AOD-9604fat loss (failed phase 2b trials), cartilage and joint injury in animals | 0.25 mg to 1 mg oral daily / day | once daily | clinical trial |
| BPC-157tendon, ligament and muscle healing, gut lining and ulcers, inflammation (animal studies) | 250 mcg to 500 mcg / dose, 1 to 2 times daily | once or twice daily | commonly reported |
| BPC-157 + TB-500 blendinjury recovery and tissue repair (user reports; no trial has tested the pair together) | 500 mcg to 1000 mcg total (250 to 500 mcg of each) / dose, 1 to 2 times daily | once or twice daily | commonly reported |
| Cagrilintideweight loss, appetite control, paired with semaglutide (CagriSema) | 0.3 mg to 4.5 mg / week | once weekly | clinical trial |
| CJC-1295 (DAC)sustained growth hormone and IGF-1 elevation (phase 1 and 2 trials), body composition (user reports) | 30 mcg/kg to 60 mcg/kg / single dose | once weekly | clinical trial |
| CJC-1295 (no DAC)growth hormone release, body composition, sleep and recovery (user reports) | 100 mcg to 200 mcg / dose, 1 to 3 times daily | once to three times daily | commonly reported |
| CJC-1295 + Ipamorelin blendgrowth hormone release, sleep, recovery and body composition (user reports; no trial of the pair) | 200 mcg to 400 mcg total (100 to 200 mcg of each) / dose, 1 to 3 times daily | once to three times daily | commonly reported |
| DSIPsleep onset and quality, stress, withdrawal (older European studies) | 25 nmol/kg IV (about 1.5 mg at 70 kg) / dose | nightly or 3 to 4 nights a week | clinical trial |
| Epitalonaging markers, melatonin rhythm, telomerase activity in cells | 10 mg per injection, courses of 5 injections / injection | once daily during a course | published study |
| GHK-Cuskin repair and collagen, wound healing, hair growth, gene expression linked to tissue remodeling | 1 mg to 2 mg / day | once daily (some every other day) | commonly reported |
| GHRP-2growth hormone release and GH deficiency testing (approved in Japan as a diagnostic), body composition and appetite (user reports) | 1 mcg/kg / single dose | two to three times daily | published study |
| GHRP-6growth hormone release (human studies from 1990 on), appetite, heart and tissue protection (animal studies) | 0.1 mcg/kg to 1 mcg/kg / single dose | two to three times daily | published study |
| GLOW blendskin, hair and tissue repair (each component separately; the blend itself has no studies) | 2 mg to 4 mg of blend per injection (10 to 20 units at 20 mg/mL) / day | once daily, 5 to 7 days a week | commonly reported |
| Glutathioneoxidative stress, liver support, Parkinson's symptom pilot, skin lightening (IV clinics) | 1,400 mg IV three times a week / infusion | 2 to 3 times a week | clinical trial |
| Hexarelingrowth hormone release (human studies), heart protection (animal studies), GH deficiency testing | 1 mcg/kg to 2 mcg/kg / single dose | once to three times daily | published study |
| IGF-1 LR3muscle growth and nitrogen retention in rats, cell culture growth factor; muscle and recovery (user reports) | 20 mcg to 80 mcg / day | once daily | commonly reported |
| Ipamorelingrowth hormone release, body composition, sleep, recovery (user reports); post-operative gut motility (early trial) | 200 mcg to 300 mcg / dose, 1 to 2 times daily | once or twice daily, some users 3 times | commonly reported |
| Kisspeptin-10LH, FSH and testosterone release, fertility research, sexual response (kisspeptin-54 studies) | 0.3 nmol/kg to 10 nmol/kg IV bolus (about 30 mcg to 900 mcg at 70 kg) / dose | 2 to 3 times a week (community); continuous exposure blunts the LH response | clinical trial |
| KLOW blendwound and tissue repair, skin, gut inflammation (each component separately; the blend itself has no studies) | 2 mg to 4 mg of blend per injection (10 to 20 units at 20 mg/mL) / day | once daily, some split morning and evening | commonly reported |
| KPVgut inflammation and colitis in mice, skin inflammation, wound models | 200 mcg to 500 mcg per injection / injection | once or twice daily | commonly reported |
| LL-37chronic wound healing (topical trial), biofilms and infection in the lab, immune signaling | 0.5 mg/mL to 1.6 mg/mL topical, twice weekly / application | once daily, 5 days a week (community); twice weekly topical (trial) | clinical trial |
| Melanotan Itanning and sunburn protection, light sensitivity in erythropoietic protoporphyria (FDA approved as a 16 mg implant) | 16 mg implant every 2 months / 2 months | daily while loading (community) or 5 days a week (trial), then 1 to 2 times a week | FDA label |
| Melanotan IIskin tanning, sexual arousal (the PT-141 precursor) | 0.01 mg/kg to 0.03 mg/kg (0.7 mg to 2.1 mg at 70 kg) / day | daily or every other day while loading, then 1 to 2 times a week | clinical trial |
| MOTS-cinsulin sensitivity, fat gain on a high-fat diet, exercise capacity and aging (mouse studies) | 0.5 mg/kg to 5 mg/kg / day, intraperitoneal | two to three times weekly | animal study |
| NAD+energy and fatigue, addiction recovery clinics, aging markers | 750 mg over 6 hours IV / infusion | subcutaneous: 1 to 3 times a week, up to daily; IV: 1 to 5 sessions a week in a course | clinical trial |
| Pinealonmemory and attention in older adults (Russian reports), neuron protection in cells | 10 mg to 20 mg per day / day | once daily during a course | commonly reported |
| PT-141low sexual desire in premenopausal women (FDA approved), erectile response in men (phase 2 only) | 1.75 mg / dose | as needed, no more than once in 24 hours; label caps at 8 doses a month | FDA label |
| Retatrutideweight loss, type 2 diabetes blood sugar, fatty liver, knee osteoarthritis with obesity | 1 mg to 12 mg / week | once weekly | clinical trial |
| Selankanxiety, asthenia, stress, attention | 250 mcg to 300 mcg per application, about 900 mcg per day / application | 1 to 3 applications per day | published study |
| Semaglutideweight loss, type 2 diabetes blood sugar, cardiovascular risk reduction, fatty liver (MASH) | 0.25 mg to 2.4 mg / week | once weekly | FDA label |
| Semaxmemory and attention, recovery after stroke and head injury, stress tolerance | 200 mcg to 2,000 mcg per application, 800 mcg to 8,000 mcg per day / application | 2 to 4 applications per day | published study |
| Sermorelingrowth hormone deficiency in children (former FDA approval), pituitary function testing, adult GH support and sleep (compounded off-label use) | 30 mcg/kg / day, at bedtime | once daily, often 5 nights on and 2 off | FDA label |
| SS-31Barth syndrome muscle strength (FDA accelerated approval 2025), mitochondrial myopathy, heart failure and dry AMD trials | 40 mg once daily / day | once daily, same time each day | FDA label |
| TB-500wound and tissue repair, cell migration, heart and eye repair (thymosin beta-4 trials), flexibility and injury recovery (user reports) | 2 mg to 2.5 mg / dose, 2 to 3 times weekly (loading) | twice weekly while loading, then once weekly | commonly reported |
| Tesamorelinexcess abdominal (visceral) fat in HIV-associated lipodystrophy (approved), fatty liver, cognition in older adults (trials) | 1.28 mg / day | once daily | FDA label |
| Thymosin Alpha-1chronic hepatitis B and C, immune support during chemotherapy, sepsis and severe infection trials | 1.6 mg twice weekly / dose | twice weekly, 3 to 4 days apart | clinical trial |
| Tirzepatideweight loss, type 2 diabetes blood sugar, obstructive sleep apnea | 2.5 mg to 15 mg / week | once weekly | FDA label |
| Wolverine blendinjury recovery and tissue repair (user reports; no trial has tested the pair together) | 500 mcg to 2000 mcg total (250 to 1000 mcg of each) / day | once or twice daily | commonly reported |
Green means an FDA label, blue a published human trial, amber a commonly reported range with no human trial behind it. Start at the low end, and talk to a clinician.
How to read these
A dose range is only useful with the mix that goes with it. Each chart gives one easy reconstitution (for example 5 mg in 2 mL) and the units for every dose in the range at that mix, so you can go straight from the chart to the syringe. Change the mix with the calculator if your vial is a different size.